ZA989885B - Use of macrolides for the treatment of cancer and macular degeneration - Google Patents

Use of macrolides for the treatment of cancer and macular degeneration

Info

Publication number
ZA989885B
ZA989885B ZA989885A ZA989885A ZA989885B ZA 989885 B ZA989885 B ZA 989885B ZA 989885 A ZA989885 A ZA 989885A ZA 989885 A ZA989885 A ZA 989885A ZA 989885 B ZA989885 B ZA 989885B
Authority
ZA
South Africa
Prior art keywords
macrolides
cancer
treatment
macular degeneration
macular
Prior art date
Application number
ZA989885A
Other languages
English (en)
Inventor
Yat Sun Or
Jacob J Plattner
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of ZA989885B publication Critical patent/ZA989885B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
ZA989885A 1997-10-31 1998-10-29 Use of macrolides for the treatment of cancer and macular degeneration ZA989885B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96147397A 1997-10-31 1997-10-31

Publications (1)

Publication Number Publication Date
ZA989885B true ZA989885B (en) 1999-05-05

Family

ID=25504514

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA989885A ZA989885B (en) 1997-10-31 1998-10-29 Use of macrolides for the treatment of cancer and macular degeneration

Country Status (17)

Country Link
EP (1) EP1027060A2 (ko)
JP (1) JP2001521891A (ko)
KR (1) KR20010031577A (ko)
CN (1) CN1278178A (ko)
AR (1) AR043071A1 (ko)
AU (1) AU1206799A (ko)
BG (1) BG104436A (ko)
BR (1) BR9813318A (ko)
CA (1) CA2307850A1 (ko)
HU (1) HUP0100012A3 (ko)
IL (1) IL135518A0 (ko)
NO (1) NO20002189L (ko)
PL (1) PL340604A1 (ko)
SK (1) SK6172000A3 (ko)
TR (1) TR200001147T2 (ko)
WO (1) WO1999022722A2 (ko)
ZA (1) ZA989885B (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5037771B2 (ja) 2000-04-13 2012-10-03 バイオチカ テクノロジー リミテッド グリコシル化されたハイブリッド産物およびその産生方法と利用
EP1539157B1 (en) 2002-09-18 2013-08-21 Trustees Of The University Of Pennsylvania Rapamycin for use in inhibiting or preventing choroidal neovascularization
US7091196B2 (en) 2002-09-26 2006-08-15 Rib-X Pharmaceuticals, Inc. Bifunctional heterocyclic compounds and methods of making and using same
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
CA2520732C (en) 2003-03-28 2012-12-04 Sloan-Kettering Institute For Cancer Research Migrastatin analogs and uses thereof
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
EP2716647A3 (en) 2004-02-27 2014-08-20 Rib-X Pharmaceuticals, Inc. Macrocyclic compounds and methods of making and using the same
CN1950388A (zh) * 2004-02-27 2007-04-18 瑞伯-X医药品有限公司 大环化合物以及其制作和使用方法
US8957056B2 (en) 2004-05-25 2015-02-17 Sloan-Kettering Instiute For Cancer Research Migrastatin analogs in the treatment of cancer
US8188141B2 (en) 2004-09-23 2012-05-29 Sloan-Kettering Institute For Cancer Research Isomigrastatin analogs in the treatment of cancer
BRPI0608152A2 (pt) 2005-02-09 2009-11-10 Macusight Inc formulações para tratamento ocular
CA2615990A1 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
US8470985B2 (en) 2005-08-24 2013-06-25 Rib-X Pharmaceuticals, Inc. Triazole compounds and methods of making and using the same
US8278281B2 (en) 2005-08-24 2012-10-02 Rib-X Pharmaceuticals, Inc. Triazole compounds and methods of making and using the same
CA2635797C (en) 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
WO2007112052A2 (en) 2006-03-23 2007-10-04 Macusight, Inc. Formulations and methods for vascular permeability-related diseases or conditions
CN106317146B (zh) * 2015-06-18 2019-06-21 沈阳药科大学 双环克拉霉素衍生物及其作为肿瘤细胞增值抑制剂的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6461090A (en) * 1989-10-30 1991-05-02 Abbott Laboratories Injectable formulation for lipophilic drugs
US5498424A (en) * 1994-11-30 1996-03-12 Klein; Ira Method of treating obesity

Also Published As

Publication number Publication date
KR20010031577A (ko) 2001-04-16
JP2001521891A (ja) 2001-11-13
HUP0100012A2 (hu) 2001-05-28
CN1278178A (zh) 2000-12-27
BG104436A (en) 2000-12-29
WO1999022722A3 (en) 1999-08-05
HUP0100012A3 (en) 2003-07-28
EP1027060A2 (en) 2000-08-16
TR200001147T2 (tr) 2000-08-21
NO20002189L (no) 2000-06-28
WO1999022722A2 (en) 1999-05-14
BR9813318A (pt) 2000-08-22
AR043071A1 (es) 2005-07-20
CA2307850A1 (en) 1999-05-14
NO20002189D0 (no) 2000-04-27
IL135518A0 (en) 2001-05-20
SK6172000A3 (en) 2001-03-12
PL340604A1 (en) 2001-02-12
AU1206799A (en) 1999-05-24

Similar Documents

Publication Publication Date Title
PL347942A1 (en) Device for the treatment of macular degeneration
ZA989885B (en) Use of macrolides for the treatment of cancer and macular degeneration
ZA979096B (en) Viral and cancer treatment
AP9700939A0 (en) Compounds and methods for the treatment of cancer
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
AU2212299A (en) Compositions and methods for the treatment of tumor
HUP0102473A3 (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
IL127739A0 (en) Retinoyloxy (substituted) alkylene butyrates useful for the treatment of cancer and other proliferative diseases
AU2476200A (en) Ribozyme therapy for the treatment and/or prevention of restenosis
GB9811598D0 (en) Diagnosis and treatment of cancer
IL141426A0 (en) Compositions and methods for the treatment of tumor
IL143212A0 (en) Compositions and methods for the treatment of tumor
AU8068198A (en) Methods for treating human cancers
AU2529799A (en) Benzofuran-4-carboxamides and their therapeutic use
GB9819999D0 (en) Treatment of cancer
ZA984650B (en) Intratumoral administration of triphenylethylenes for the treatment of cancer
EP1023076A4 (en) USE OF THE P-TEN TUMOR SUPPRESSOR GENE IN THE DIAGNOSIS AND TREATMENT OF CANCER
GB9828564D0 (en) Materials and methods for the treatment and diagnosis of cancer
AU6288698A (en) Apparatus for stimulating the human body
AU6404698A (en) Treatment methods for obtaining therapeutic products and resulting products
AU4406899A (en) Progesterone treatment of cancer
AU3205295A (en) Antisense oligonucleotides and methods for the treatment of schistosomiasis
ZA988293B (en) Compositions and methods for the treatment of tumor.
GB9703517D0 (en) Steroid treatment
AUPO955497A0 (en) Treatment of cancer